Medical Data Vision Inkomsten in het verleden
Verleden criteriumcontroles 1/6
Medical Data Vision has been growing earnings at an average annual rate of 6.6%, while the Healthcare Services industry saw earnings growing at 17.3% annually. Revenues have been growing at an average rate of 10.6% per year. Medical Data Vision's return on equity is 10.6%, and it has net margins of 7.2%.
Belangrijke informatie
6.6%
Groei van de winst
7.6%
Groei van de winst per aandeel
| Healthcare Services Groei van de industrie | 19.2% |
| Inkomstengroei | 10.6% |
| Rendement op eigen vermogen | 10.6% |
| Nettomarge | 7.2% |
| Volgende winstupdate | 11 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Medical Data Vision (TSE:3902) Will Pay A Dividend Of ¥6.50
Oct 03
Medical Data Vision (TSE:3902) Has Affirmed Its Dividend Of ¥6.50
Sep 19Medical Data Vision (TSE:3902) Has Affirmed Its Dividend Of ¥6.50
Aug 10Medical Data Vision Co., Ltd. (TSE:3902) Stocks Shoot Up 25% But Its P/E Still Looks Reasonable
Jun 25Why Medical Data Vision Co., Ltd. (TSE:3902) Could Be Worth Watching
Jun 13Opbrengsten en kosten
Hoe Medical Data Vision geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 6,197 | 448 | 3,601 | 68 |
| 31 Mar 24 | 6,248 | 689 | 3,368 | 68 |
| 31 Dec 23 | 6,419 | 979 | 3,192 | 68 |
| 30 Sep 23 | 6,264 | 753 | 2,948 | 332 |
| 30 Jun 23 | 6,250 | 793 | 2,989 | 332 |
| 31 Mar 23 | 6,152 | 832 | 2,965 | 332 |
| 31 Dec 22 | 6,104 | 870 | 2,939 | 332 |
| 30 Sep 22 | 6,047 | 1,164 | 2,933 | 316 |
| 30 Jun 22 | 5,893 | 1,125 | 2,878 | 316 |
| 31 Mar 22 | 5,754 | 1,091 | 2,816 | 316 |
| 31 Dec 21 | 5,672 | 1,087 | 2,733 | 316 |
| 30 Sep 21 | 5,378 | 872 | 3,013 | 0 |
| 30 Jun 21 | 5,168 | 865 | 2,906 | 0 |
| 31 Mar 21 | 4,966 | 858 | 2,783 | 0 |
| 31 Dec 20 | 4,579 | 700 | 2,736 | 0 |
| 30 Sep 20 | 4,422 | 770 | 2,676 | 0 |
| 30 Jun 20 | 4,286 | 700 | 2,632 | 0 |
| 31 Mar 20 | 4,199 | 637 | 2,611 | 0 |
| 31 Dec 19 | 4,026 | 554 | 2,559 | 0 |
| 30 Sep 19 | 3,931 | 522 | 2,416 | 0 |
| 30 Jun 19 | 3,891 | 329 | 2,437 | 0 |
| 31 Mar 19 | 3,743 | 188 | 2,456 | 0 |
| 31 Dec 18 | 3,577 | 69 | 2,428 | 0 |
| 30 Sep 18 | 3,519 | 137 | 2,345 | 0 |
| 30 Jun 18 | 3,364 | 182 | 2,275 | 0 |
| 31 Mar 18 | 3,283 | 257 | 2,155 | 0 |
| 31 Dec 17 | 3,225 | 354 | 2,037 | 0 |
| 30 Sep 17 | 3,009 | 178 | 1,939 | 0 |
| 30 Jun 17 | 2,929 | 272 | 1,838 | 0 |
| 31 Dec 16 | 2,632 | 178 | 1,743 | 0 |
Kwaliteitswinsten: 3902 has a high level of non-cash earnings.
Groeiende winstmarge: 3902's current net profit margins (7.2%) are lower than last year (12.7%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 3902's earnings have grown by 6.6% per year over the past 5 years.
Versnelling van de groei: 3902's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 3902 had negative earnings growth (-43.5%) over the past year, making it difficult to compare to the Healthcare Services industry average (11.9%).
Rendement op eigen vermogen
Hoge ROE: 3902's Return on Equity (10.6%) is considered low.